Desoxyrhaponticin
Based on 1 publication(s) in Google Scholar
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.80%
- CAS No.: 30197-14-9
- Formule: C21H24O8
- Masse moléculaire:404.41
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-K1051
Hygromycin B, Sterile -
HY-N0686
PseudoprotodioscinSREBPs/microRNA 33a/b Inhibitor -
HY-120394
TVB-3166FASN Inhibitor -
HY-N2486R
Desoxyrhaponticin (Standard)FASN Inhibitor -
HY-N0083
BetulinEndogenous Metabolite -
HY-N0288
LycorineSCAP Inhibitor -
HY-12364A
trans-C75C75 Enantiomer -
HY-13447A
PF429242 dihydrochlorideS1P Inhibitor -
HY-111551
FT113FASN Inhibitor -
HY-B0218
OrlistatFASN Inhibitor -
HY-12364
C75Fatty Acid Synthase Inhibitor -
HY-12325
GSK2194069FASN Inhibitor
Publications Citing Use of MedChemExpress (MCE) Desoxyrhaponticin
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
300 μg
Compound: 6a
|
Inhibition of adenosine diphosphate-induced platelet aggregation in human platelet-rich plasma
Inhibition of adenosine diphosphate-induced platelet aggregation in human platelet-rich plasma
|
[PMID: 9392877] |
| Platelet | IC50 |
40.4 μg
Compound: 6a
|
Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma
Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma
|
[PMID: 9392877] |
In Vitro
The IC50s values for inhibition of renal membrane vesicle uptake in normal rats and diabetic rats were 118.8 and 115.7 μM, respectively. Desoxyrhaponticin effectively controls hyperglycemia by inhibiting glucose transport in the small intestine and inhibiting glucose reabsorption in the kidneys[2].
Desoxyrhaponticin inhibits glucose uptake in rabbit intestinal mesangial vesicles and rat everted intestinal cuffs with IC50s of 148.3 and 30.9 μMs, respectively[2].
Desoxyrhaponticin (500 μM) inhibits glucose uptake into rabbit intestinal brush-border membrane vesicles, IC50=30.9 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 30197-14-9
-
Appearance Solid
-
Masse moléculaire 404.41
-
Formule C21H24O8
-
Color White to off-white
-
SMILES
COC(C=C1)=CC=C1/C=C/C2=CC(O)=CC(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)CO)=C2
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biomed Res Int
Anti-influenza A Virus Effects and Mechanisms of Emodin and Its Analogs via Regulating PPAR α/ γ-AMPK-SIRT1 Pathway and Fatty Acid Metabolism. [Abstract]2021 Sep 9;2021:9066938. PMID: 34540999
Solvant et solubilité
In Vitro:
DMSO : 83.33 mg/mL (206.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Li P, et al. Inhibitory effect of desoxyrhaponticin and rhaponticin, two natural stilbene glycosides from the Tibetan nutritional food Rheum tanguticum Maxim. ex Balf., on fatty acid synthase and human breast cancer cells. [Content Brief]
[2]. Li JM, et al. Desoxyrhaponticin (3,5-dihydroxy-4'-methoxystilbene 3-O-beta-D-glucoside) inhibits glucose uptake in the intestine and kidney: In vitro and in vivo studies. J Pharmacol Exp Ther. 2007 Jan;320(1):38-46. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4727 mL | 12.3637 mL | 24.7274 mL | 61.8185 mL |
| 5 mM | 0.4945 mL | 2.4727 mL | 4.9455 mL | 12.3637 mL | |
| 10 mM | 0.2473 mL | 1.2364 mL | 2.4727 mL | 6.1818 mL | |
| 15 mM | 0.1648 mL | 0.8242 mL | 1.6485 mL | 4.1212 mL | |
| 20 mM | 0.1236 mL | 0.6182 mL | 1.2364 mL | 3.0909 mL | |
| 25 mM | 0.0989 mL | 0.4945 mL | 0.9891 mL | 2.4727 mL | |
| 30 mM | 0.0824 mL | 0.4121 mL | 0.8242 mL | 2.0606 mL | |
| 40 mM | 0.0618 mL | 0.3091 mL | 0.6182 mL | 1.5455 mL | |
| 50 mM | 0.0495 mL | 0.2473 mL | 0.4945 mL | 1.2364 mL | |
| 60 mM | 0.0412 mL | 0.2061 mL | 0.4121 mL | 1.0303 mL | |
| 80 mM | 0.0309 mL | 0.1545 mL | 0.3091 mL | 0.7727 mL | |
| 100 mM | 0.0247 mL | 0.1236 mL | 0.2473 mL | 0.6182 mL |
Desoxyrhaponticin Related Classifications
HY-N2486 Related Classifications
Powered by Bioz